XL 495
Alternative Names: XL-495Latest Information Update: 14 Oct 2024
At a glance
- Originator Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action PKMYT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Oct 2024 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06630247)
- 08 Oct 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06630247)
- 07 Jan 2024 Exelixis plans to file an Investigational New Drug (IND) application in Solid tumours in the second half of 2024